Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
Jin Q, Director, Market Development and Strategy at PackGene Biotech, Inc., reposted from PackGene Biotech, Inc. on LinkedIn:
”I summarized the 2025’s Most Impactful Cell and Gene Therapy Milestones:
First personalized N-of-1 CRISPR therapy successfully treated an infant with CPS1 deficiency using mRNA-based adenine base editing (NEJM milestone).
First FDA-approved nonprofit gene therapy: Telethon’s lentiviral stem cell therapy (Waskyra) for Wiskott–Aldrich syndrome.
Dual-AAV hearing restoration achieved as Regeneron’s DB-OTO restored functional hearing in congenitally deaf children.
Five-year durability validated for CSL Behring’s Hemgenix, confirming long-term efficacy of one-time AAV gene therapy in hemophilia B.
Non-viral base editing advances with Beam’s BEAM-101 showing curative potential in sickle cell disease without DNA double-strand breaks.
Gene regulation emerges as a modality as Encoded Therapeutics’ ETX101 delivered major seizure reduction in Dravet syndrome.
Expanded SMA access following FDA approval of intrathecal Zolgensma for older pediatric patients.
Huntington’s gene therapy momentum tempered as uniQure’s AMT-130 gained Breakthrough status but faced late-stage regulatory delays.
CAR-T therapies expand beyond oncology, delivering deep remissions in lupus, myasthenia gravis, and stiff person syndrome.
In vivo CAR-T and RNA reprogramming gain traction, signaling a shift away from ex vivo cell manufacturing.
Regulatory acceleration intensifies, with widespread Breakthrough, Fast Track, and RMAT designations across CGT modalities.
DMD gene therapy faces renewed scrutiny, following safety events and mixed Phase 3 outcomes with systemic AAV delivery.
Cardiac gene therapy matures, with clinical progress in inherited cardiomyopathies and regenerative heart failure programs.
Ocular gene therapy enters commercialization phase, supported by durable efficacy, regulatory confidence, and pharma partnerships.
AAV expands into metabolic and neurodegenerative diseases, including late-stage GSDIa, ALS, and pancreas-targeted GLP-1 gene therapies.”
Quoting PackGene Biotech, Inc.‘s post:
”2025: A Landmark Year for Cell and Gene Therapy – Key Milestones and Insights
At PackGene, we’ve closely monitored these developments. Our latest Learning Center article, “2025’s Most Impactful Cell and Gene Therapy Milestones” provides a comprehensive breakdown of the successes and challenges that defined the year.
Key Highlights from 2025 include:
- Precision Medicine Firsts: The successful administration of a bespoke CRISPR base-editing therapy for an infant with CPS1 deficiency.
- Regulatory Milestones: Landmark FDA approvals, including the first non-profit developed lentiviral gene therapy.
- Clinical Success: Five-year data showing functional cures for Hemophilia and major progress in AAV9-mediated delivery for SMA.
- Pipeline Expansion: A significant surge in AAV clinical trials.”
Find the full article here.
Stay updated with Hemostasis Today.
-
Jul 23, 2026, 10:33Johanna Rodríguez: The Structural Challenge of Next-Gen Anticoagulants
-
Jul 23, 2026, 10:27Logan Hamilton: New Study Identifies the Mutated Antibody Gene Responsible for VITT
-
Jul 23, 2026, 09:05Fonkou Steve: What If We’ve Been Asking the Wrong Question About Plasma Too?
-
Jul 23, 2026, 08:27Registration Is Now Open for ASH 2026
-
Jul 23, 2026, 08:19Sheeza Nawaz: Why Do Patients With Aortic Stenosis Bleed?
-
Jul 23, 2026, 07:59Paschalis Karakasis: Can Left Atrial Appendage Closure Truly Replace Oral Anticoagulation?
-
Jul 23, 2026, 06:53Lakmali Silva: What Makes ISTH More Than a Scientific Meeting?
-
Jul 23, 2026, 05:48Paschalis Evangelidis: Rethinking Pulmonary Embolism Through the Lens of Thromboinflammation
-
Jul 23, 2026, 05:35Neil Morgan: Honoured to Lead the Platelet and Megakaryocyte Theme at ISTH 2026